Kratochwil, C., Giesel, F. L., Mier, W., & Haberkorn, U. (2014). Bi-213-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: A first-in-human experience. European journal of nuclear medicine and molecular imaging, 41(11), . https://doi.org/10.1007/s00259-014-2857-9
Chicago-Zitierstil (17. Ausg.)Kratochwil, Clemens, Frederik L. Giesel, Walter Mier, und Uwe Haberkorn. "Bi-213-DOTATOC Receptor-targeted Alpha-radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-human Experience." European Journal of Nuclear Medicine and Molecular Imaging 41, no. 11 (2014). https://doi.org/10.1007/s00259-014-2857-9.
MLA-Zitierstil (9. Ausg.)Kratochwil, Clemens, et al. "Bi-213-DOTATOC Receptor-targeted Alpha-radionuclide Therapy Induces Remission in Neuroendocrine Tumours Refractory to Beta Radiation: A First-in-human Experience." European Journal of Nuclear Medicine and Molecular Imaging, vol. 41, no. 11, 2014, https://doi.org/10.1007/s00259-014-2857-9.